stockportfolio.pro
NeuroPace, Inc. (NPCE)
Healthcare · Medical Devices · NasdaqGM
NeuroPace, Inc. revenue & earnings — last 6 fiscal years
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $41.14M | $45.18M | $45.52M | $65.42M | $79.91M | $99.99M |
| Gross profit | $30.27M | $33.44M | $32.49M | $48.12M | $59.09M | $77.22M |
| Net income | $-24.28M | $-36.08M | $-47.08M | $-32.96M | $-27.14M | $-21.46M |
| Net margin | -59.0% | -79.9% | -103.4% | -50.4% | -34.0% | -21.5% |
Source: NeuroPace, Inc. SEC filings (10-K).
Explore 6 years of NeuroPace, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track NPCE in your portfolio →
NeuroPace, Inc. financial history by metric
About NeuroPace, Inc.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
NeuroPace, Inc. — frequently asked questions
What is NeuroPace, Inc.'s revenue?
NeuroPace, Inc. (NPCE) reported revenue of $99.99M for fiscal year 2025, up 25.1% from the prior year, according to its SEC filings.
Is NeuroPace, Inc. profitable?
No — NPCE reported a net loss of $-21.46M in fiscal 2025.
What is NPCE's P/E ratio?
NeuroPace, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is NeuroPace, Inc. growing?
NPCE's revenue grew at roughly 19.4% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does NeuroPace, Inc. have?
As of fiscal year 2025, NPCE carried roughly $58.88M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is NeuroPace, Inc.'s gross margin?
NPCE's gross margin was 77.2% in fiscal 2025 — gross profit of $77.22M on revenue of $99.99M.
What is NeuroPace, Inc.'s market cap?
NeuroPace, Inc. (NPCE) has a market capitalization of about $533.23M, based on the latest data in our nightly-refreshed cache.
When does NeuroPace, Inc.'s fiscal year end?
NPCE's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from NeuroPace, Inc.'s official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.